# OnCo record ter-2013 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ter-2013/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ter-2013" ;
  schema:name "TER-2013"@en ;
  schema:description "TER-2013 is an experimental oral small-molecule inhibitor from Terremoto Biosciences, in phase 1 trials for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer and ovarian cancer and other cancers."@en ;
  schema:url <https://onco.cc/drugs/ter-2013/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://terremotobio.com/pipeline/>, <https://terremotobio.com/pipeline/>, <https://terremotobio.com/press-release/terremoto-biosciences-granted-fda-fast-track-designation-for-ter-2013-an-akt1-selective-small-molecule-inhibitor-for-breast-cancer/>, <https://clinicaltrials.gov/api/v2/studies/NCT07109726>, <https://clinicaltrials.gov/search?intr=TER-2013> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral small-molecule inhibitor (AKT1-selective)" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:targets <https://onco.cc/targets/akt/> ;
  onco:companies <https://onco.cc/companies/terremoto-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct07109726/> .